Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review

Forest Plots

Updated September 16, 2021

Prepared by:

International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health

and

World Health Organization





For comments or questions, please contact: Melissa Higdon at mhigdon@jhu.edu.

TABLE OF CONTENTS

Methods for Inclusion in Forest Plots	3
Abbreviations	4
Forest Plots by Vaccine	5
Ad26.COV2.S (Janssen)	5
AZD1222 (AstraZeneca)	6
BNT162b2 (Pfizer)	7
CoronaVac (Sinovac)	8
mRNA-1273 (Moderna)	9
Heterologous schedules	10
Forest Plots by Disease Outcome	11
Death	11
Severe Disease	11
Symptomatic Disease	12
Any Infection	12
Asymptomatic Infection	13
Forest Plots by Variant of Concern	14
Alpha	14
Beta	14
Gamma	15
Delta	15

METHODS FOR INCLUSION IN FOREST PLOTS

Vaccine Effectiveness (VE) estimates included in these plots are from an ongoing systematic review of COVID-19 vaccine effectiveness studies. Complete details on the method of the systematic review as well as a summary table of results can be found on the VIEW-hub Resources Page (https://view-hub.org/resources):

- "COVID-19 Vaccine Effectiveness and Impact Studies Review Methods"
- "COVID-19 Vaccine Effectiveness Results Summary Table"

The VE estimates included in the plots are a large subset of the estimates abstracted from the systematic literature review. A single study can include many VE estimates. In an effort to not overrepresent the amount of evidence that exists for each vaccine, the following criteria are used to determine which VE estimates are displayed in the forest plots located on the VIEW-hub resources page (https://view-hub.org/resources). There are some instances when more than one estimate from a study will be displayed in the same plot (e.g. a study includes VE estimates from two distinct populations or estimates for different variants). Reference numbers are included for each VE estimate displayed so users can identify when a study is represented more than once within a plot. More information on each reference can be found in the weekly literature review summary table located on VIEW-HUB (https://view-hub.org/resources).

- Complete vaccination is defined as ≥7 days post final dose; partial vaccination is defined as ≥14 days post first dose of a 2-dose vaccine.
- If a study reports results for the same outcome for both combined and individual vaccines, only individual vaccine
 VE estimates are displayed. This criterion only apples to studies evaluating VE of BNT162b2 (Pfizer) and mRNA-1273
 (Moderna) vaccines.
- If a study reports results from 2 different evaluation designs (e.g. test-negative design and cohort design) on the same population, VE estimates from the primary analysis only are displayed.
- If a study reports overall VE as well as variant-specific VE estimates for the same disease outcome, overall VE estimates are included in the 'By Vaccine' and 'By Disease Outcome' plots. However, if a study reports only variant-specific VE estimates, then all variant VE estimates are displayed and labeled. For the 'By Variant' plots, variant-specific estimates are included from all studies in which they are available. Note that studies may be conducted in the context of circulating variants, however, if variant-specific estimates (i.e. VE is stratified by variant) are not provided, estimates are labeled as 'overall' VE estimates, unless otherwise noted.
- If a study reports VE estimates for the same disease outcome for different populations, the general population VE estimate is displayed when available. If a general population estimate is not available, the VE from each population is displayed (exception is when there are estimates for similar age groups in which case the more stable VE estimate will be displayed).
- If a study reports VE estimates on more than one 'severe' disease outcome (e.g. 'severe disease', 'hospitalization', and 'ICU admission'), the more inclusive disease outcome including a larger population is displayed. These different types of severe outcomes are labeled as 'severe disease' in the plots, however it is important to keep in mind that the definition of severe disease varies and may explain some differences in VE estimates for severe disease outcomes.

ABBREVIATIONS

asymp = asymptomatic

HCW = healthcare workers

HHC = household contacts

LTCF = long-term care facility


pop = population

SNF= skilled nursing facility

VOC = variant of concern


By VACCINE

Ad26.COV2.S (Janssen) Vaccine Effectiveness, 1 Dose




AZD1222 (AstraZeneca) Vaccine Effectiveness, 1 Dose

(ref no) country, population, variant




AZD1222 (AstraZeneca) Vaccine Effectiveness, 2 Doses




BNT162b2 (Pfizer) Vaccine Effectiveness, 1 Dose BNT162b2 (Pfizer) Vaccine Effectiveness, 2 Doses (ref no) country, population, variant (ref no) country, population, variant (39) Denmark, priority groups, overall (21) Israel, general pop, overall (26) Israel, general pop, overall (48) Israel, general pop, overall (39) Denmark, priority groups, overall (9) UK - England, >70 years, overall Death (96) UK - England, general pop. alpha -о-Death (41) Italy, general pop, overall -(96) UK - England, general pop, alpha -(96) UK - England, general pop, delta -(96) UK - England, general pop, delta (34) Canada, general pop, overall (50) Canada, general pop, non-VOC (50) Canada, general pop, alpha (50) Canada, general pop, beta & gamma (50) Canada, general pop, non-VOC <u>~</u>~ (50) Canada, general pop, alpha Canada, general pop, beta & gamma-(39) Denmark, priority groups, overall-(71) France, LTCF residents, beta-(3) Israel, general pop, overall-(26) Israel, general pop, overall-(26) Israel, general pop, overall-(60) Israel, pregnant women, overall-(82") Israel, 260 years, overall-(92) Israel, pregnant women, overall-(50) Canada, general pop, beta & gamma (50) Canada, general pop, delta Ç (39) Denmark, priority groups, overall (3) Israel, general pop, overall (27) Qatar, general pop, alpha (27) Qatar, general pop, beta -0-(75) Qatar, general pop, delta (92) Israel , pregnant women, overall (41) Italy, general pop, overall (27) Qatar, general pop, alpha (83) Qatar, ≥ 12 years, overall Severe -0 (35) Spain, general pop, overall (27) Qatar, general pop, alpna -(27) Qatar, general pop, beta -(74) Qatar, transplant patients, overall -(75) Qatar, general pop, delta -(83*) Qatar, ≥ 12 years, overall -(35) Spain, general pop, overall -(31) UK, 80+ years, overall -(43) UK, hospital patients, alpha -(31) UK, 70-79 years, overall Severe (43) UK hospital patients alpha (43) UK, hospital patients, delta (4) UK - England, > 80 years, overall -(9) UK - England, >70 years, overall (43) ÜK, hospital patients, alpha(3) UK, hospital patients, delta(17) UK. England, 80-83 years, overall(96) UK - England, general pop, alpha(96) UK - England, general pop, delta(96) UK - England, general pop, overall(52) USA, hospital patients, overall(73) USA, general pop, overall(81) USA, ≥ 12 years, overall(91) USA, ≥ 50 years, overall(93) USA, general pop, overall-(17) UK - England, 80-83 years, overall (96) UK - England, general pop, alpha (96) UK - England, general pop, delta (19) UK - Scotland, general pop, overall (91) USA, ≥ 50 years, overall (34) Canada, general pop, overall (50) Canada, general pop, non-VOC (50) Canada, general pop, alpha -0-(50) Canada, general pop, beta & gamma -(34) Canada, general pop, overall-(50) Canada, general pop, non-VOC -(50) Canada, general pop, alpha-(50) Canada, general pop, beta & gamma-(50) Canada, general pop, delta (66) Canada, HCW, overall (50) Canada, general pop, delta (66) Canada, HCW, overall (3) Israel, general pop, overall (60) Israel, pregnant women, overall (3) Israel , general pop, overall (13) Israel , HCW, overall (26) Israel , general pop, overall (28) Israel , HCW, overall (28) Israel , HCW, overall (92) Israel, pregnant women, overall-(24) Italy, HCW, overall (75) Qatar, general pop, delta (60) Israel , pregnant women, overall (85) Israel , HCW, overall Symptomatic (83) Qatar, ≥ 12 years, overall disease (85) srael, HCW, overall + (92) Israel, pregnant women, overall - (24) Italy, HCW, overall - (75) Qatar, general pop, delta - (83*) Qatar, general pop, overall - (35) Spain, general pop, overall - (33) UK, ≥65 years, overall - (57) UK, general pop, overall - (63) UK, general pop, alpha - (63) UK, general pop, delta - (2) UK - England, > 80 years, overall - (96) UK - England, > 80 years, overall - (96) UK - England, > 80 years, overall - (96) UK - England, > 80 years, overall - (96) UK - England, > 80 years, overall - (86) UK - England, > 80 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - England, > 90 years, overall - (96) UK - (96) WK - (96) WK - (96) WK - (96) W Symptomatic (35) Spain, general pop, overall (20) UK, general pop, overall (33) UK, ≥65 years, overall -(57) UK, general pop, overall -(63) UK, general pop, alpha (63) UK, general pop, delta -ō-(2) UK - England, > 80 years, overall (9) UK - England, >70 years, overall -0-(96) UK - England, general pop, alpha (96) UK - England, general pop, delta (66) Canada, HCW, overall-(5) Denmark, LTCF residents, overall-(5) Denmark, LTCF staff, overall-(39) Denmark, priority groups (67) UK, FR, NL, PT, ES, SE, ≥ 65 years, overall-_ (40) Canada, >70 years, overall 9) Denmark, priority groups, overall (71) France, LTCF residents, beta (66) Canada, HCW, overall (5) Denmark, LTCF residents, overall (3) Israel , general pop, overall (21) Israel , general pop, overall (26) Israel , general pop, overall (48) Israel , general pop, overall (58) Israel , HHC of cases, overall (5) Denmark, LTCF staff, overall -0 (39) Denmark, priority groups, overall -⊸~ (3) Israel, general pop, overall (58) Israel, HHC of cases, overall (60) Israel, pregnant women, overall (81) Israel, HHC of cases, overall (82*) Israel, 40-59 years, overall (82*) Israel, 40-59 years, overall (82*) Israel, 40-59 years, overall (82*) Israel, HCW, overall (92) Israel, pregnant women, overall (41) Italy, general pop, overall (70) Kuwait, HCW, overall (70) Kuwait, HCW, overall (70) Netherlands, HHC of cases, overall (27) Qatar, general pop, beta (27) Qatar, general pop, beta (74) Qatar, transplant patients, overall (75) Qatar, general pop, delta (75) Qatar, general pop, (60) Israel, pregnant women, overall (92) Israel , pregnant women, overall (24) Italy, HCW, overall · (41) Italy, general pop, overall -(70) Kuwait, HCW, overall (72) Netherlands, HHC of cases, overall (27) Qatar, general pop, alpha -(27) Qatar, general pop, beta (75) Qatar, general pop, delta -(83) Qatar, ≥ 12 years, overall 4) Qatar, fransplant patients, overall-(75) Qatar, general pop, delta -(83*) Qatar, ≥ 12 years, overall-(42) Scotland, general pop, delta -(42) Scotland, general pop, overall-(35) Spain, general pop, overall-(16) Sweden, general pop, overall-(18) UK, HCW, overall-(68) UK, 50-64 years, overall-(79) UK, general pon, alpha period (42) Scotland, general pop, alpha (42) Scotland, general pop, delta (23) Spain, HCW, overall (35) Spain, general pop, overall -(16) Sweden, general pop, overall (10) UK, LTCF residents, overall-(68) UK, 50-64 years, overall -(79) UK, general pop, alpha period -(79) UK, general pop, delta period -(14) USA, general pop, overall -(14) USA, general pop, overall -(47) USA, general pop, overall -(62) USA, general pop, overall -(73) USA, general pop, overall -(73) USA, general pop, overall -(80) USA, SNF residents, overall -(15) UK, general pop, overall (18) UK, HCW, overall (20) UK, general pop, overall (45) UK, HCW, overall (68) UK, 50-64 years, overall -(79) UK, general pop, alpha period (79) UK, general pop, delta period (80) USA, surgery patients, overall (81) USA, ≥ 12 years, overall (17) UK - England, 80-83 years, overall (47) USA, general pop, overall (13) Israel, HCW, overall (13) Israel, ⊓Cvv, overall (26) Israel, general pop, overall (28) Israel, HCW, overall (75) Qatar, general pop, delta (83*) Qatar, ≥ 12 years, overall (75) Qatar, general pop, delta Asymp (83) Qatar, ≥ 12 years, overall infection (6) USA, hospital patients, overall-75 50 25 50 100 25 75 100 Effectiveness Effectiveness * Indicates estimates evaluating vaccine effectiveness at ≥ 6 months from final dose

CoronaVac (Sinovac) Vaccine Effectiveness, 1 Dose

(ref no) country, population, variant




CoronaVac (Sinovac) Vaccine Effectiveness, 2 Doses




mRNA-1273 (Moderna) Vaccine Effectiveness, 1 Dose


(ref no) country, population, variant



mRNA-1273 (Moderna) Vaccine Effectiveness, 2 Doses




AZD1222 (AstraZeneca) 1st dose plus BNT162b2 (Pfizer) or mRNA-1273 (Moderna) 2nd dose Vaccine Effectiveness




By DISEASE OUTCOME

Vaccine Effectiveness against Death due to COVID-19, Complete Vaccination

(ref no) country, population, variant




Vaccine Effectiveness against COVID-19 Severe Disease, Complete Vaccination




Vaccine Effectiveness against COVID-19 Symptomatic Disease, Complete Vaccination


(ref no) country, population, variant




Vaccine Effectiveness against COVID-19 Infection (Any), Complete Vaccination




Vaccine Effectiveness against COVID-19 Asymptomatic Infection, Complete Vaccination






By Variant of Concern

Vaccine Effectiveness against Alpha Variant, Complete Vaccination




Vaccine Effectiveness against Beta Variant, Complete Vaccination



Vaccine Effectiveness against Gamma Variant, Complete Vaccination

(ref no) country, population, variant



Note: Gamma-specific VE not available. Study conducted in context of high Gamma prevalence (79%).

Vaccine Effectiveness against Delta Variant, Complete Vaccination

